ArticleApplied and environmental microbiology2019
Using an Endogenous CRISPR-Cas System for Genome Editing in the Human Pathogen Clostridium difficile.
Article in Applied and environmental microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 59 citations in OpenAlex.
- Occurrence and applications of CRISPR-Cas systems in bifidobacteria.Applied and environmental microbiology · 2026Review
- Functional characterization of a type I-F1 CRISPR-cas system from the clinical isolate Shewanella xiamenensis Sh95 reveals constitutive activity and plasmid-curing capability.Scientific reports · 2026Article
- Generating Targeted Mutants Using a Riboswitch to Control Plasmid Behavior During Allelic Exchange Mutagenesis.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Visualizing C. difficile During Murine Infection.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Structural determinants of SlpA-mediated phage recognition in Clostridioides difficile.PLoS pathogens · 2025Article
- Rapid detection ofActa biochimica et biophysica Sinica · 2025Article
- Engineering the Microbiome: a Novel Approach to Managing Autoimmune Diseases.Neuromolecular medicine · 2025Review
- Hi-TARGET: a fast, efficient and versatile CRISPR type I-B genome editing tool for the thermophilic acetogen Thermoanaerobacter kivui.Biotechnology for biofuels and bioproducts · 2025Article
- Defense arsenal of the strict anaerobemBio · 2025Article
- Regulatory networks: Linking toxin production and sporulation in Clostridioides difficile.Anaerobe · 2025Review
- Article
- Theophylline-based control of repA on a Clostridioides difficile plasmid for use in allelic exchange.Anaerobe · 2024Article
- Removal of mobile genetic elements from the genome ofFrontiers in microbiology · 2024Article
- Identification of an anti-CRISPR protein that inhibits the CRISPR-Cas type I-B system inmSphere · 2023Article
- Foodborne Clostridioides Species: Pathogenicity, Virulence and Biocontrol Options.Microorganisms · 2023Review
- Virulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027) Clostridioides difficile.Cell reports · 2023Article
- Repurposing the atypical type I-G CRISPR system for bacterial genome engineering.Microbiology (Reading, England) · 2023Article
- A network of small RNAs regulates sporulation initiation in Clostridioides difficile.The EMBO journal · 2023Article
- Novel ribotype/sequence type associations and diverse CRISPR-Cas systems in environmental Clostridioides difficile strains from northern Iraq.FEMS microbiology letters · 2023Article
- Endogenous CRISPR/Cas systems for genome engineering in the acetogensFrontiers in bioengineering and biotechnology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human enteropathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.